Decline of microtubule-associated protein tau after experimental stroke in differently aged wild-type and 3xTg mice with Alzheimer-like alterations

Neuroscience

Volumn 330, Issue , 2016, Pages 1-11

  Michalski, Dominik ^a   Preißler, Hartmut ^a   Hofmann, Sarah ^a   Kacza, Johannes ^a   Härtig, Wolfgang ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Cytoskeleton; Ischemic stroke; Microtubule; Tau

Indexed keywords

NEURON SPECIFIC NUCLEAR PROTEIN; TAU PROTEIN; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; MAPT PROTEIN, HUMAN; MAPT PROTEIN, MOUSE; NERVE PROTEIN; NEUN PROTEIN, MOUSE; NUCLEAR PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; BRAIN REGION; BRAIN TISSUE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CYTOSKELETON; FEMALE; IMMUNOFLUORESCENCE TEST; IMMUNOREACTIVITY; MALE; MOUSE; NERVE INJURY; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; TRANSGENIC MOUSE; WEIGHT REDUCTION; WILD TYPE MOUSE; 129 MOUSE; AGING; ANIMAL; BRAIN; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HUMAN; METABOLISM; PATHOLOGY;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; BRAIN ISCHEMIA; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; MICE, 129 STRAIN; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; STROKE; TAU PROTEINS; WEIGHT LOSS;

EID: 84971372913     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2016.05.013     Document Type: Article

References (48)

1. Arendt T. Neurodegeneration and plasticity. Int J Dev Neurosci 2004, 22:507-514.
2. Astrup J., Siesjö B.K., Symon L. Thresholds in cerebral ischemia - the ischemic penumbra. Stroke 1981, 12:723-725.
3. Baas P.W., Qiang L. Neuronal microtubules: when the MAP is the roadblock. Trends Cell Biol 2005, 15:183-187.
4. Ballatore C., Brunden K.R., Huryn D.M., Trojanowski J.Q., Lee V.M., Smith A.B. Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies. J Med Chem 2012, 55:8979-8996.
5. Berkhemer O.A., Fransen P.S., Beumer D., van den Berg L.A., Lingsma H.F., Yoo A.J., Schonewille W.J., Vos J.A., Nederkoorn P.J., Wermer M.J., van Walderveen M.A., Staals J., Hofmeijer J., van Oostayen J.A., Lycklama à Nijeholt G.J., Boiten J., Brouwer P.A., Emmer B.J., de Bruijn S.F., van Dijk L.C., Kappelle L.J., Lo R.H., van Dijk E.J., de Vries J., de Kort P.L., van Rooij W.J., van den Berg J.S., van Hasselt B.A., Aerden L.A., Dallinga R.J., Visser M.C., Bot J.C., Vroomen P.C., Eshghi O., Schreuder T.H., Heijboer R.J., Keizer K., Tielbeek A.V., den Hertog H.M., Gerrits D.G., van den Berg-Vos R.M., Karas G.B., Steyerberg E.W., Flach H.Z., Marquering H.A., Sprengers M.E., Jenniskens S.F., Beenen L.F., van den Berg R., Koudstaal P.J., van Zwam W.H., Roos Y.B., van der Lugt A., van Oostenbrugge R.J., Majoie C.B., Dippel D.W. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015, 372:11-20. MR CLEAN Investigators.
6. Billingsley M.L., Kincaid R.L. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J 1997, 323:577-591.
7. Boxer A.L., Lang A.E., Grossman M., Knopman D.S., Miller B.L., Schneider L.S., Doody R.S., Lees A., Golbe L.I., Williams D.R., Corvol J.C., Ludolph A., Burn D., Lorenzl S., Litvan I., Roberson E.D., Höglinger G.U., Koestler M., Jack C.R., Van Deerlin V., Randolph C., Lobach I.V., Heuer H.W., Gozes I., Parker L., Whitaker S., Hirman J., Stewart A.J., Gold M., Morimoto B.H. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 2014, 13:676-685. AL-108-231 Investigators.
8. Butner K.A., Kirschner M.W. Tau protein binds to microtubules through a flexible array of distributed weak sites. J Cell Biol 1991, 115:717-730.
9. Cairns N.J., Lee V.M., Trojanowski J.Q. The cytoskeleton in neurodegenerative diseases. J Pathol 2004, 204:438-449.
10. Dirnagl U., Iadecola C., Moskowitz M.A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999, 22:391-397.
11. Dittmar M., Spruss T., Schuierer G., Horn M. External carotid artery territory ischemia impairs outcome in the endovascular filament model of middle cerebral artery occlusion in rats. Stroke 2003, 34:2252-2257.
12. Dong D.W., Zhang Y.S., Yang W.Y., Wang-Qin R.Q., Xu A.D., Ruan Y.W. Hyperphosphorylation of tau protein in the ipsilateral thalamus after focal cortical infarction in rats. Brain Res 2014, 1543:280-289.
13. Donnan G.A., Fisher M., Macleod M., Davis S.M. Stroke. Lancet 2008, 371:1612-1623.
14. Dirks M., Niessen L.W., van Wijngaarden J.D., Koudstaal P.J., Franke C.L., van Oostenbrugge R.J., Huijsman R., Lingsma H.F., Minkman M.M., Dippel D.W. Promoting thrombolysis in acute ischemic stroke. Stroke 2011, 42:1325-1330. PRomoting ACute Thrombolysis in Ischemic StrokE (PRACTISE) Investigators.
15. Endres M., Engelhardt B., Koistinaho J., Lindvall O., Meairs S., Mohr J.P., Planas A., Rothwell N., Schwaninger M., Schwab M.E., Vivien D., Wieloch T., Dirnagl U. Improving outcome after stroke: overcoming the translational roadblock. Cerebrovasc Dis 2008, 25:268-278.
16. Geddes J.W., Schwab C., Craddock S., Wilson J.L., Pettigrew L.C. Alterations in tau immunostaining in the rat hippocampus following transient cerebral ischemia. J Cereb Blood Flow Metab 1994, 14:554-564.
17. Gendron T.F., Petrucelli L. The role of tau in neurodegeneration. Mol Neurodegener 2009, 4:13.
18. Hacke W., Kaste M., Bluhmki E., Brozman M., Dávalos A., Guidetti D., Larrue V., Lees K.R., Medeghri Z., Machnig T., Schneider D., von Kummer R., Wahlgren N., Toni D., Investigators E.C.A.S.S. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008, 359:1317-1329.
19. Hawkes C.A., Michalski D., Anders R., Nissel S., Grosche J., Bechmann I., Carare R.O., Härtig W. Stroke-induced opposite and age-dependent changes of vessel-associated markers in co-morbid transgenic mice with Alzheimer-like alterations. Exp Neurol 2013, 250:270-281.
20. Hesse C., Rosengren L., Andreasen N., Davidsson P., Vanderstichele H., Vanmechelen E., Blennow K. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after stroke. Neurosci Lett 2001, 297:187-190.
21. Holzer M., Holzapfel H.P., Zedlick D., Brückner M.K., Arendt T. Abnormally phosphorylated tau protein in Alzheimer's disease: heterogeneity of individual regional distribution and relationship to clinical severity. Neuroscience 1994, 63:499-516.
22. Koike M.A., Garcia F.G., Kitazawa M., Green K.N., Laferla F.M. Long term changes in phospho-APP and tau aggregation in the 3xTg-AD mice following cerebral ischemia. Neurosci Lett 2011, 495:55-59.
23. Krüger L., Mandelkow E.M. Tau neurotoxicity and rescue in animal models of human tauopathies. Curr Opin Neurobiol 2015, 36:52-58.
24. Li Y., Jiang N., Powers C., Chopp M. Neuronal damage and plasticity identified by microtubule-associated protein 2, growth-associated protein 43, and cyclin D1 immunoreactivity after focal cerebral ischemia in rats. Stroke 1998, 29:1972-1980.
25. Li X., Kumar Y., Zempel H., Mandelkow E.M., Biernat J., Mandelkow E. Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration. EMBO J 2011, 30:4825-4837.
26. Lian T., Qu D., Zhao X., Yu L., Gao B. Identification of site-specific stroke biomarker candidates by laser capture microdissection and labeled reference peptide. Int J Mol Sci 2015, 16:13427-13441.
27. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu Rev Neurosci 2001, 24:1121-1159.
28. Longa E.Z., Weinstein P.R., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989, 20:84-91.
29. Maccioni R.B., Cambiazo V. Role of microtubule-associated proteins in the control of microtubule assembly. Physiol Rev 1995, 75:835-864.
30. Magen I., Gozes I. Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP). Neuropeptides 2013, 47:489-495.
31. Meairs S., Wahlgren N., Dirnagl U., Lindvall O., Rothwell P., Baron J.C., Hossmann K., Engelhardt B., Ferro J., McCulloch J., Kaste M., Endres M., Koistinaho J., Planas A., Vivien D., Dijkhuizen R., Czlonkowska A., Hagen A., Evans A., De Libero G., Nagy Z., Rastenyte D., Reess J., Davalos A., Lenzi G.L., Amarenco P., Hennerici M. Stroke research priorities for the next decade - a representative view of the European scientific community. Cerebrovasc Dis 2006, 22:75-82.
32. Menzies S.A., Hoff J.T., Betz A.L. Middle cerebral artery occlusion in rats: a neurological and pathological evaluation of a reproducible model. Neurosurgery 1992, 31:100-106.
33. Michalski D., Härtig W., Krügel K., Edwards R.H., Böddener M., Böhme L., Pannicke T., Reichenbach A., Grosche A. Region-specific expression of vesicular glutamate and GABA transporters under various ischaemic conditions in mouse forebrain and retina. Neuroscience 2013, 231:328-344.
34. Morimoto B.H., Fox A.W., Stewart A.J., Gold M. Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases. Expert Rev Clin Pharmacol 2013, 6:483-502.
35. Mozaffarian D., Benjamin E.J., Go A.S., Arnett D.K., Blaha M.J., Cushman M., Das S.R., de Ferranti S., Després J.P., Fullerton H.J., Howard V.J., Huffman M.D., Isasi C.R., Jiménez M.C., Judd S.E., Kissela B.M., Lichtman J.H., Lisabeth L.D., Liu S., Mackey R.H., Magid D.J., McGuire D.K., Mohler E.R., Moy C.S., Muntner P., Mussolino M.E., Nasir K., Neumar R.W., Nichol G., Palaniappan L., Pandey D.K., Reeves M.J., Rodriguez C.J., Rosamond W., Sorlie P.D., Stein J., Towfighi A., Turan T.N., Virani S.S., Woo D., Yeh R.W., Turner M.B. Executive summary: heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 2016, 133:447-454. American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
36. Mullen R.J., Buck C.R., Smith A.M. NeuN, a neuronal specific nuclear protein in vertebrates. Development 1992, 116:201-211.
37. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease: intracellular Aβ and synaptic dysfunction. Neuron 2003, 39:409-421.
38. Petry F.R., Pelletier J., Bretteville A., Morin F., Calon F., Hébert S.S., Whittington R.A., Planel E. Specificity of anti-tau antibodies when analysing mice models of Alzheimer's disease: problems and solutions. PLoS One 2014, 9:e94251.
39. Raskin J., Cummings J., Hardy J., Schuh K., Dean R.A. Neurobiology of Alzheimer's disease: integrated molecular, physiological, anatomical, biomarker, and cognitive dimensions. Curr Alzheimer Res 2015, 12:712-722.
40. Rudrabhatla P. Regulation of neuronal cytoskeletal protein phosphorylation in neurodegenerative diseases. J Alzheimers Dis 2014, 41:671-684.
41. Shackelford D.A., Yeh R.Y. Dephosphorylation of tau during transient forebrain ischemia in the rat. Mol Chem Neuropathol 1998, 34:103-120.
42. Sharp F.R., Lu A., Tang Y., Millhorn D.E. Multiple molecular penumbras after focal cerebral ischemia. J Cereb Blood Flow Metab 2000, 20:1011-1032.
43. Song B., Ao Q., Wang Z., Liu W., Niu Y., Shen Q., Zuo H., Zhang X., Gong Y. Phosphorylation of tau protein over time in rats subjected to transient brain ischemia. Neural Regen Res 2013, 8:3173-3182.
44. Tashiro K., Hasegawa M., Ihara Y., Iwatsubo T. Somatodendritic localization of phosphorylated tau in neonatal and adult rat cerebral cortex. NeuroReport 1997, 8:2797-2801.
45. Wang Y., Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci 2016, 17:22-35.
46. Wen Y., Yang S., Liu R., Simpkins J.W. Transient cerebral ischemia induces site-specific hyperphosphorylation of tau protein. Brain Res 2004, 1022:30-38.
47. Zhang Z.G., Bower L., Zhang R., Chen S., Windham J.P., Chopp M. Three-dimensional measurement of cerebral microvascular plasma perfusion, glial fibrillary acidic protein and microtubule associated protein-2 immunoreactivity after embolic stroke in rats: a double fluorescent labeled laser-scanning confocal microscopic study. Brain Res 1999, 844:55-66.
48. Zheng G.Q., Wang X.M., Wang Y., Wang X.T. Tau as a potential novel therapeutic target in ischemic stroke. J Cell Biochem 2010, 109:26-29.